30 May | 2023
The BBRC participates in the Euro-PAD neuroimaging symposium
At the symposium, attendees had the opportunity to discuss the main research advances in the field, as well as plan future activities.
The European working group involved in the EPAD and AMYPAD projects, in which the BarcelonaBeta Brain Research Center (BBRC), research center of the Pasqual Maragall Foundation, is participating, has met in London with the aim of debating the latest developments in the field of neuroimaging and Alzheimer's biomarkers, and look for new lines of research and funding.
At the Euro-PAD neuroimaging symposium, which was held from May 24 to 25, attendees had the opportunity to discuss the main research advances in the field, as well as plan future activities. The consortium's collaborators are still working to find future collaborations that can promote research in the prevention of Alzheimer’s.
The meeting had the participation of Marc Suárez Calvet, head of the Biomarkers Research Group in Fluids and Translational Neurology of the BBRC, who spoke about the general vision of the consortia and cohorts affiliated to Euro-PAD and their scientific objectives during the presentation of the conferences.
The symposium program has also included various interventions by research staff linked to the BBRC:
- Raffaele Cacciaglia has offered the intervention "CSF Aβ42/40 is associated with neurodegeneration independently of CSF p-tau in the earliest AD continuum”.
- Mahnaz Shekari, for her part, presented the talk "Evaluating the sensitivity of Centiloid quantification to pipeline design and image harmonization”.
- Gemma Salvadó has intervened with her presentation "CSF MTBR-tau243 is a specific biomarker of tau pathology in Alzheimer's disease”.
- Finally, Irene Cumplido participated with a short talk entitled "Neuroimaging brain-age delta as mediator between modifiable risk factors and longitudinal cognition in preclinical Alzheimer's Disease".
More information
EPAD (European Prevention of Alzheimer's Dementia Consortium), funded by the Innovative Medicines Initiative (IMI), was an interdisciplinary research program with the participation of 39 European organizations to optimise the testing and development of preventive treatments for Alzheimer’s.
AMYPAD (Amyloid Imaging to Prevent Alzheimer's Disease), funded by the Horizon 2020 research and innovation program of the European Union, has consisted of a European collaboration with 17 institutions involved to improve knowledge, diagnosis and treatment of Alzheimer's through the use of a cerebral positron emission tomography (PET).
